Axoltis Pharma

📍 Lyon, France👥 17 employees💰 Last funded Nov 2025
Biotechnology Research🌐 axoltis.com
Website LinkedIn
Axoltis Pharma is developing NX210c, a groundbreaking treatment for Amyotrophic Lateral Sclerosis (ALS, also known as maladie de Charcot in French), the most frequent of the rare diseases and one of the most devastating. ALS progressively destroys motor neurons, leading to muscle weakness, paralysis, and ultimately death, with very limited treatment options today. NX210c is the first targeted - and most advanced - treatment addressing this high unmet medical need. This peptide restores the blood-brain barrier (BBB), a key factor in ALS, Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. With 7 patents and orphan drug designation in the USA and EU for ALS, NX210c has shown an excellent tolerability profile and is currently being evaluated in a Phase 2 clinical trial on 80 patients, with topline results expected in April 2026. Axoltis, nominated for the prestigious Prix Galien, is a pioneer in BBB restoration and is accelerating the development of NX210c, bringing new hope to millions of patients facing neurodegenerative diseases.
4
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

4 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
France
3
United States
1
Investor activity2020–2025 · investors recorded per year
2020120253
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Axoltis Pharma?
Axoltis Pharma has 4 investors on record on gritt.io.
When did Axoltis Pharma last raise funding?
The most recent investment in Axoltis Pharma recorded on gritt.io was in November 2025.
What industry is Axoltis Pharma in?
Axoltis Pharma operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Axoltis Pharma based?
Axoltis Pharma is headquartered in Lyon, France.